Sheryl Stevenson

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.

The annual Mission Cataract program allows staff to extend its mission to people who need assistance due to unfortunate circumstances.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Gareth Lema, MD, PhD, discusses an innovative eye stroke program at Mount Sinai Health System that involves collaboration among ophthalmologists, the stroke service, and emergency department physicians.

The program — entitled “Pumping Adrenaline!” — brings viewers myriad challenging cases, intraoperative complications, and complex problems following cataract surgery.

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.

As ophthalmologists observe Cataract Awareness Month this June, William L. Soscia, MD, medical director at Center for Sight, in Sarasota, Florida, focuses on the importance of having excellent vision for safety and everyday functions.

Ophthalmic World Leaders (OWL) will be hosting an OWL Connect event during the American-European Congress of Ophthalmic Surgery (AECOS) 2022 Summer Symposium, Saturday, July 9.

Ophthalmic World Leaders (OWL) invites members of the ophthalmic community who are based near Fort Worth, Texas, to celebrate the launch of its new chapter in Texas.

Tennessee Academy of Ophthalmology’s doctor of the month shares what excites him about ophthalmology, his biggest career challenge, and chocolate as his favorite comfort food.

Participate by May 20 in the annual Ophthalmic Business and Leadership Trends Survey for 2022.

Expansion of program aims to provide more children with improved eye care; enhance the teaching of Wills residents and fellows

The Cleveland Eye Bank Foundation's 2nd Annual Golf Tournament, "Keep Your Eye on the Ball," is happening Monday, June 20, at Pine Hills Golf Club.

Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.

Orbis' Nicolas Jaccard, PhD, principal AI architect, discusses the impact that AI can have on health care, including current applications for AI in glaucoma, the challenges of acceptance of AI in clinical settings, how AI has helped with the diagnosis of glaucoma, and the vision for the future of AI in glaucoma and eye care in general.

Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.

Orbis International celebrates 40 years of innovation this year, beginning in 1982 with their iconic flying eye hospital. Since their start, Orbis has continued their innovation, working to achieve sustainable and scalable impact in the countries where they work. Doris Macharia, MD, senior vice president of global programs with Orbis, talks with Ophthalmology Times' Sheryl Stevenson, reflecting on the last 40 years and what's to come.

April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.

Dr. Rishi Raj Borah, Country Director with Orbis India, discusses recent research he co-authored showing the top 3 barriers keeping families from accessing cataract treatment for their children in India.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Kathryn A. Colby, MD, PhD, discusses Fuchs’ dystrophy symptoms and treatment options as well as the underlying concept of Descemet stripping only surgery and her role in pioneering this technique.